KZR 261
Alternative Names: KZR 834; KZR-261Latest Information Update: 28 Oct 2024
At a glance
- Originator Kezar Life Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action SEC translocation channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Parenteral, Injection)
- 31 Aug 2024 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Parenteral)
- 13 Aug 2024 Efficacy data from a phase I trial in Solid tumours released by Kezar Life Sciences